ImmVira Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 18

Employees

  • Latest Deal Type
  • Series C1

  • Latest Deal Amount
  • $8M

  • Investors
  • 22

ImmVira General Information

Description

Developer of biopharmaceutical technology in the field of immunotherapy designed to provide medical solutions to treat cancer and tumor. The company operates as a biotechnology platform focused on the development of oncolytic viruses and vector-type approaches for the treatment of cancer and its products include genetically engineered Oncolytic Herpes Simplex Virus that target metastatic tumors or tumors inaccessible by direct injection, thereby enabling patients to receive better tumor treatment and solutions.

Contact Information

Website
www.immviragroup.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Building 2, Floor 12
  • Silver Star Hi-tech Industrial Park, Longhua District
  • Shenzhen, Guangdong
  • China
+86 0755
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Building 2, Floor 12
  • Silver Star Hi-tech Industrial Park, Longhua District
  • Shenzhen, Guangdong
  • China
+86 0755

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ImmVira Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series C1) 30-Sep-2022 $8M Completed Clinical Trials - General
7. Later Stage VC (Series C) 31-Dec-2020 Completed Clinical Trials - General
6. Later Stage VC (Series B1) 24-Sep-2020 Completed Clinical Trials - General
5. Early Stage VC (Series B) 15-Jun-2020 Completed Clinical Trials - General
4. Early Stage VC (Series A1) 31-Jan-2019 Completed Clinical Trials - General
3. Early Stage VC (Series A) 20-Sep-2017 Completed Startup
2. Early Stage VC 13-Sep-2016 Completed Startup
1. University Spin-Out 28-May-2015 Completed Startup
To view ImmVira’s complete valuation and funding history, request access »

ImmVira Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of biopharmaceutical technology in the field of immunotherapy designed to provide medical solutions to treat c
Biotechnology
Shenzhen, China
18 As of 2023

Plymouth Meeting, PA
 

Santa Monica, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ImmVira Competitors (3)

One of ImmVira’s 3 competitors is Inovio Pharmaceuticals, a Corporation company based in Plymouth Meeting, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Kite Pharma Formerly VC-backed Santa Monica, CA
Bluebird Bio Formerly VC-backed Somerville, MA
You’re viewing 3 of 3 competitors. Get the full list »

ImmVira Patents

  • 60

    Total Documents Applications and Grants

  • Total Patents Families

  • 27

    Granted

  • 29

    Pending

  • Expiring in next 12 mo

ImmVira Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021392709-A1 Oncolytic herpes simplex type 1 viruses for treatment of brain tumors Pending 04-Dec-2020
CA-3203135-A1 Oncolytic herpes simplex type 1 viruses for treatment of brain tumors Pending 04-Dec-2020
EP-4256038-A1 Oncolytic herpes simplex type 1 viruses for treatment of brain tumors Pending 04-Dec-2020
AU-2021392709-A9 Oncolytic herpes simplex type 1 viruses for treatment of brain tumors Pending 04-Dec-2020
JP-2023552203-A Oncolytic herpes simplex virus type i for the treatment of brain tumors - patents.com Pending 04-Dec-2020 C12N7/00
To view ImmVira’s complete patent history, request access »

ImmVira Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ImmVira Investors (22)

Investor Name Investor Type Holding Investor Since Participating Rounds
China Merchants Capital Asset Manager Minority
Jiangsu Wuzhong Industrial Company Corporation Minority
Unifortune Investment Asset Manager Minority
China Merchants Venture Capital Corporate Venture Capital Minority
Greater Bay Area Homeland Venture Capital Minority
You’re viewing 5 of 22 investors. Get the full list »

Ready to get started?

Request a free trial

ImmVira FAQs

  • When was ImmVira founded?

    ImmVira was founded in 2015.

  • Where is ImmVira headquartered?

    ImmVira is headquartered in Shenzhen, China.

  • What is the size of ImmVira?

    ImmVira has 18 total employees.

  • What industry is ImmVira in?

    ImmVira’s primary industry is Biotechnology.

  • Is ImmVira a private or public company?

    ImmVira is a Private company.

  • What is the current valuation of ImmVira?

    The current valuation of ImmVira is .

  • What is ImmVira’s current revenue?

    The current revenue for ImmVira is .

  • How much funding has ImmVira raised over time?

    ImmVira has raised $91M.

  • Who are ImmVira’s investors?

    China Merchants Capital, Jiangsu Wuzhong Industrial Company, Unifortune Investment, China Merchants Venture Capital, and Greater Bay Area Homeland are 5 of 22 investors who have invested in ImmVira.

  • Who are ImmVira’s competitors?

    Inovio Pharmaceuticals, Kite Pharma, and Bluebird Bio are competitors of ImmVira.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »